DTT + JASPER for Autism
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on finding the best way to improve language skills in preschoolers with autism who have limited verbal abilities. It aims to determine how different intervention methods, such as DTT (Discrete Trial Training, a form of Applied Behavior Analysis) and JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation), can enhance communication by age six. The study tests various combinations and intensities of these treatments to tailor the approach to each child's needs. Eligible children have been diagnosed with autism, have fewer than 20 functional words in their vocabulary, and have participated in early intervention or preschool for at least three months. As an unphased trial, this study offers a unique opportunity to contribute to pioneering research that could significantly enhance communication strategies for children with autism.
Do I need to stop my current medications for the trial?
The trial requires that participants have stable medication for the past 6 months, so you should not change your current medications if you want to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that both JASPER and DTT are safe and well-tolerated treatments for children with autism. JASPER, a play-based therapy, helps children improve social skills and communication without major side effects. Studies have found that children in these programs demonstrate significant improvements in joint attention and play skills, which are crucial for development.
DTT, or Discrete Trial Training, is a teaching method that breaks down skills into small, easy-to-learn steps. Research supports its effectiveness for children with autism, ages 3 to 11. This method teaches new skills through repetition and positive feedback.
Both treatments aim to enhance developmental skills in children with autism, and studies report no significant adverse effects, suggesting they are safe and well-tolerated options for young children.12345Why are researchers excited about this trial?
Researchers are excited about the DTT (Discrete Trial Training) and JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) techniques for autism because they offer tailored, responsive approaches to therapy. Unlike current standard treatments like Applied Behavior Analysis (ABA), these methods can adapt to a child's individual response rate. If a child responds quickly to either DTT or JASPER, they continue with the same treatment, but slower responders receive either an enhanced or intensified version of their therapy. This flexibility allows for more personalized and potentially more effective interactions, aiming to improve developmental outcomes in children with autism.
What evidence suggests that this trial's treatments could be effective for autism?
Research has shown that JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation), one of the treatments in this trial, can greatly enhance social communication skills in children with autism. Studies indicate that children participating in JASPER often experience improved joint engagement and play skills. Joint engagement is crucial, accounting for 69% of the improvement in children's social communication abilities.
Similarly, Discrete Trial Training (DTT), another treatment option in this trial, is a proven method for assisting children with autism. DTT breaks skills into smaller, manageable steps and has improved social skills through structured teaching. Research has found that children with autism who participate in DTT show significant improvements in specific behaviors and learning outcomes. Both JASPER and DTT effectively help children with autism develop essential communication and social skills.12678Are You a Good Fit for This Trial?
The PRISM study is for preschoolers aged 36-59 months with Autism Spectrum Disorder who speak less than 20 functional words. They must have had over 3 months of early intervention, stable medication for the past half year, and a nonverbal mental age above one year. Children with sensory/motor impairments or genetic syndromes like Down Syndrome are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Stage 1 Treatment
Participants receive either JASPER or DTT intervention for 10 weeks, 2 hours per week
Stage 2 Treatment
Early responders continue with the same intervention; slow responders are re-randomized to either intensify the current intervention or switch to Combined & Enhanced Treatment (CET)
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 10 weeks post-treatment and at age 6
What Are the Treatments Tested in This Trial?
Interventions
- DTT
- JASPER
DTT is already approved in United States for the following indications:
- Autism Spectrum Disorder
- Developmental Delays
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor